## • enago

Purpose: <u>Combination therapy of Ffenofibrate</u> and stating <u>combination therapy</u> is highly recommended by the current clinical guidelines for <u>the</u> treatment of mixed dyslipidemia. In this study, <u>we formulated</u> an innovative delayed-release preparation of fenofibrate <u>was designed</u> to <u>achieve the following: to reduce the risk of muscle toxicity; (caused by simultaneous administration of this combination therapy); by altering the pharmacokinetic profile of fenofibrate; <u>as well as and</u> to improve the oral bioavailability of the modified-release formulation.</u>

Methods: Micronized f Eenofibrate was used micronized to prepare drug-loaded cores via a powder powder layering process before performing multiparticulate pellet coating. Different coating formulations were screened, and their in vitro release profiles was were compared with those of the commercial sustained-release pellets Lipilfen®. Two optimized formulations were evaluated in Beagle dogs using and compared with two reference commercial preparations of fenofibrate (the immediate-release preparation Lipanthyl® and the sustained-release pellets Lipilfen®) as references.

Results: The in vivo release of fenofibrate from R1 and R2 selected from in vitro tests exhibited a lag phase, and then followed by rapid and complete drug release. The relative bioavailabilities of R1 and R2 were 100.4% and 201.1%, respectively, which were higher than that of Lipilfen® (67.2%).

Conclusion: The mModified fenofibrate pellets developed showed enhanced bioavailability and delayed-release properties, and They have the potential tocan potentially improve safety and compliance when co-administrated administered with statins. To the best of our knowledge, Tthis is the first report of a delayed-release preparation of fenofibrate preparation.

Comment [A1]: A compound modifier contains 2 or more words, which act together as one adjective and are connected by hyphens. Hyphens are used with these terms so that their meaning is understood clearly.

Comment [A2]: In academic writing, it is important to maintain parallelism in a sentence so that the items being compared can be clearly understood. Here, the sentence has been revised to clearly denote that "in vitro release profiles" are being compared.

**Comment [A3]:** This phrase was revised to maintain consistency with the phrase used previously in the text (under "Purpose").

All material in this document is the intellectual property of Crimson Interactive Pvt. Ltd. The use of information and content in this document in whole or in part is forbidden unless express permission has been given in writing by Crimson Interactive Pvt. Ltd.

www.enago.com | www.enago.ip | www.enago.com.tr | www.enago.com.br | www.enago.de | www.enago.tw | www.enago.tr | www.enago.co.kr | www.enago.ru